Noticias y eventos de ADARx Pharmaceuticals, Inc. (ADRX)ADRXADARx Pharmaceuticals, Inc.

Amaero and Bamboo Insurance Postpone IPOs

Amaero and Bamboo Insurance announced that both have postponed their planned IPOs, citing adverse market conditions.LATEST IPOS AND DIRECT LISTINGS:ADARx Pharmaceuticalsopened on September 25 at $22.10. The late-stage clinical biotechnology company developing next-generation siRNA therapeutics priced its upsized initial public offering of 26.25M shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx.RECENT SPAC IPOS:Bluerock Acquisition IIopened on September 25 at $9.98. BTIG is acting as the sole book-running manager for the offering.Live Oak Acquisition VIopened on September 23 at $10.02. Live Oak is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company may pursue an acquisition opportunity in any business or industry.PERFORMANCE:Prices as of 10:45 am ET on Monday, September 28 -ADARx Pharmaceuticals – fractionally up at $19.32.UPCOMING IPOS:Upcoming IPO and direct listings expected include Anthropic, Nscale, Altera, Brooks Automation, Aggreko, and CALM Chain.Clickto see upcoming IPO calendar on TipRanks.Anthropicis now planning to hold its IPO in November, which is later than the October listing expected by investors, The Wall Street Journal's Corrie Driebusch, Anissa Gardizy, and Kate Clark, citing people familiar with the matter. The report states that a delayed listing would allow the company to share its Q3 results and show its strong competitive position. Anthropic also intends to meet with investors in the coming days, and the meetings are expected to help the company and its bankers gauge investor appetite for the offering, WSJ noted.Nscale Limitedhas filed with the SEC for an initial public offering of its ordinary shares. The company intends to apply to list its ordinary shares on the New York Stock Exchange under the symbol "NSCL". Goldman Sachs, J.P. Morgan, Morgan Stanley are listed as the lead bookrunners.Alteraannounced that its parent company has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed public offering of its common stock. "The number of shares to be offered and the price range for the proposed offering have not yet been determined. The proposed public offering remains subject to the completion of the SEC review process, as well as market and other conditions," Altera stated. Altera, which provides high-performance, programmable compute and connectivity solutions, is backed by Silver Lake and Intel.Brooks Automationannounced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the proposed offering have not yet been determined. The initial public offering is expected to take place after the SEC completes its review process, subject to market and other conditions.Aggrekohas applied to list its ordinary shares on the New York Stock Exchange under the symbol "AGKO." No amount has been given.CALM Chainhas filed for an initial public offering of 5M Class A ordinary shares, representing 24.39% of the company's total Class A ordinary shares issued and outstanding following completion of the offering. The company is offering, on a firm commitment basis, 5M Class A ordinary shares. Following the completion of the offering, 24.39% of the Class A ordinary shares issued and outstanding will be held by public shareholders, assuming the underwriter does not exercise the over-allotment option. The company expects the initial public offering price for the offering will be between $5.00 and $7.00 per Class A ordinary share and it plans to list its Class A shares on the Nasdaq Capital Market under the symbol "CCIL".OTHER IPO NEWS:Amaeroannounced the postponement of its initial public offering due to adverse market conditions.Bamboo Insurance, a home insurance company controlled by private equity firm CVC Capital Partners, has also postponed its initial public offering, citing market conditions, according to Bloomberg's Bailey Lipschultz and Anthony Hughes, citing people familiar with the matter."Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.

ADARx Pharmaceuticals Prices IPO at $17 per Share

ADARx Pharmaceuticals, a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, priced its upsized initial public offering of 26.25M shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx.

ADARx Pharmaceuticals IPO Priced at $17, Expected to Open at $24

ADARx Pharmaceuticals indicated to open at $24, IPO priced at $17